Table 4 Results of the current market mix (‘As is’ scenario)
Current market mix | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
Population | 203 018 | 203 018 | 203 018 |
Direct healthcare costs | |||
QIVe acquisition costs | €1 196 791.70 | €1 196 791.70 | €1 196 791.70 |
QIVc acquisition costs | €152 263.58 | €152 263.58 | €152 263.58 |
Vaccine administration costs | €1 250 591.50 | €1 250 591.50 | €1 250 591.50 |
Total acquisition and administration costs | €2 599 646.77 | €2 599 646.77 | €2 599 646.77 |
Influenza cases among vaccinated HCWs | |||
Vaccination with QIVe | 4348 | 4348 | 4348 |
Vaccination with QIVc | 385 | 385 | 385 |
Influenza cases with symptoms among vaccinated HCWs | |||
HCWs with influenza and symptoms | 3167 | 3167 | 3167 |
Costs of prescribed influenza drugs | €44 021.45 | €44 021.45 | €44 021.45 |
Costs of influenza drugs without prescription | €24 023.26 | €24 023.26 | €24 023.26 |
Influenza-related GP visitsa | €15 576.76 | €15 576.76 | €15 576.76 |
Total direct healthcare costs | €2 683 268.24 | €2 683 268.24 | €2 683 268.24 |
Fiscal impact | |||
QIVe | €124 193.12 | €124 193.12 | €124 193.12 |
QIVc | €10 993.36 | €10 993.36 | €10 993.36 |
Total fiscal impact | €135 186.48 | €135 186.48 | €135 186.48 |
Indirect costs (productivity losses) | |||
QIVe | €1 698 948.29 | €1 698 948.29 | €1 698 948.29 |
QIVc | €150 388.01 | €150 388.01 | €150 388.01 |
Total indirect costs | €1 849 336.31 | €1 849 336.31 | €1 849 336.31 |
Total (direct costs + indirect costs + fiscal impact) | €4 667 791.03 | €4 667 791.03 | €4 667 791.03 |